Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single-arm, phase 3 study
| Autor: | Tadao Akizawa, Yoshimi Matsuda, Takanori Hayasaki, Hiroyasu Yamamoto, Yasuhiro Hayashi, Kiyoshi Nobori |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Anemia medicine.medical_treatment 030232 urology & nephrology Phases of clinical research 030204 cardiovascular system & hematology Target range Gastroenterology 03 medical and health sciences 0302 clinical medicine Japan Renal Dialysis Internal medicine medicine Humans Renal Insufficiency Chronic Adverse effect Dialysis Aged Aged 80 and over business.industry Hematology Middle Aged Triazoles medicine.disease Treatment Outcome Multicenter study Nephrology Pyrazoles Female Molidustat Hemodialysis business |
| Zdroj: | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 25(6) |
| ISSN: | 1744-9987 |
| Popis: | Molidustat, an orally administered hypoxia-inducible factor prolyl-hydroxylase inhibitor, is under development for the treatment of anemia of CKD. This 24-week, phase 3, single-arm, multicenter study evaluated the efficacy and safety of molidustat in Japanese patients with renal anemia who were undergoing hemodialysis and who were not receiving an erythropoiesis-stimulating agent. Twenty-five patients received molidustat at a starting dose of 75 mg once daily, which was adjusted to maintain a Hb target of ≥10.0 to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text